Switch theme
Sign up to access all valuation multiples
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
2011
385
LTM Revenue $270M
LTM EBITDA -$176M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Travere Therapeutics has a last 12-month revenue of $270M and a last 12-month EBITDA of -$176M.
In the most recent fiscal year, Travere Therapeutics achieved revenue of $233M and an EBITDA of -$266M.
Travere Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Travere Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $145M | $233M | XXX | XXX | XXX |
| Gross Profit | $204M | $134M | XXX | XXX | XXX |
| Gross Margin | 141% | 57% | XXX | XXX | XXX |
| EBITDA | -$326M | -$266M | XXX | XXX | XXX |
| EBITDA Margin | -225% | -114% | XXX | XXX | XXX |
| Net Profit | -$278M | -$111M | XXX | XXX | XXX |
| Net Margin | -192% | -48% | XXX | XXX | XXX |
| Net Debt | $314M | $319M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Travere Therapeutics's stock price is $15.
Travere Therapeutics has current market cap of $1.3B, and EV of $1.3B.
See Travere Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.3B | XXX | XXX | XXX | XXX | $-3.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Travere Therapeutics has market cap of $1.3B and EV of $1.3B.
Travere Therapeutics's trades at 5.0x LTM EV/Revenue multiple, and -7.6x LTM EBITDA.
Analysts estimate Travere Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Travere Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 5.8x | XXX | XXX | XXX |
| EV/EBITDA | -5.1x | XXX | XXX | XXX |
| P/E | -4.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTravere Therapeutics's NTM/LTM revenue growth is 59%
Travere Therapeutics's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $1.4M for the same period.
Over next 12 months, Travere Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Travere Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Travere Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 61% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -114% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -19% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -55% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 113% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 121% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 235% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Travere Therapeutics acquired XXX companies to date.
Last acquisition by Travere Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Travere Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Travere Therapeutics founded? | Travere Therapeutics was founded in 2011. |
| Where is Travere Therapeutics headquartered? | Travere Therapeutics is headquartered in United States of America. |
| How many employees does Travere Therapeutics have? | As of today, Travere Therapeutics has 385 employees. |
| Who is the CEO of Travere Therapeutics? | Travere Therapeutics's CEO is Dr. Eric M. Dube, PhD. |
| Is Travere Therapeutics publicy listed? | Yes, Travere Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Travere Therapeutics? | Travere Therapeutics trades under TVTX ticker. |
| When did Travere Therapeutics go public? | Travere Therapeutics went public in 2003. |
| Who are competitors of Travere Therapeutics? | Similar companies to Travere Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Travere Therapeutics? | Travere Therapeutics's current market cap is $1.3B |
| What is the current revenue of Travere Therapeutics? | Travere Therapeutics's last 12-month revenue is $270M. |
| What is the current EBITDA of Travere Therapeutics? | Travere Therapeutics's last 12-month EBITDA is -$176M. |
| What is the current EV/Revenue multiple of Travere Therapeutics? | Current revenue multiple of Travere Therapeutics is 5.0x. |
| What is the current EV/EBITDA multiple of Travere Therapeutics? | Current EBITDA multiple of Travere Therapeutics is -7.6x. |
| What is the current revenue growth of Travere Therapeutics? | Travere Therapeutics revenue growth between 2023 and 2024 was 61%. |
| Is Travere Therapeutics profitable? | Yes, Travere Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
